Kaitlyn D’Onofrio

DocwireNews

A recent study concluded that &ldquo;timing matters&rdquo; and that early, aggressive treatment trumps delayed, conservative treatment in children with newly diagnosed polyarticular course juvenile idiopathic <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/ask-the-authors-interview-with-research-team-behind-study-on-ra-patient-treatment-goals/">arthritis</a> (pcJIA).Much remains unknown about the disease, according to the study authors, which is the most common pediatric rheumatological disease and causes significant childhood disability. The estimated worldwide prevalence of <a href="https://www.docwirenews.com/blog/when-to-see-a-rheumatologist-for-joint-pain/">JIA</a> is about 19.4 per 100,000 for girls and 11.0 per 100,000 for boys. Its cause is unknown.&ldquo;The advent of disease-modifying antirheumatic drugs (DMARDs), particularly biologic DMARDs (bDMARDs), in the past two decades have revolutionised the treatment approaches to JIA, making it possible to target for inactive disease as the treatment goal,&rdquo; the authors wrote. &ldquo;Despite the advanced DMARD treatment, still about 50% of the patients with JIA failed to achieve inactive disease during long-term follow-up, and most of them had detectable joint damage.&rdquo;To conduct the present study, which was published in <a href="https://rmdopen.bmj.com/content/6/1/e001091">RMD Open</a>, the researchers queried the electronic medical record (EMR) system of a large U.S. Midwest pediatric rheumatology clinic. EMR data were obtained for 2,082 JIA patients who were aged between one and 19 years; were DMARD-na&iuml;ve; and were newly diagnosed with pcJIA; including subtypes of polyarthritis, oligoarthritis, psoriatic arthritis, enteritis-related arthritis and undifferentiated arthritis. Eligible patients received a pcJIA diagnosis in at least two visits by pediatric rheumatologists and visited a rheumatology clinic within six months of their diagnosis. Patients were excluded if they had inflammatory bowel disease, celiac disease, or trisomy.<h2>Study Methods, Results for JIA Treatment Strategies</h2>Early aggressive treatment patients received bDMARD and conventional synthetic DMARD (csDMARD) prescriptions during a two-month period. Conservative treatment patients received initial csDMARDs and were not prescribed bDMARDs for at least three months. Baseline was the month patients received their first DMARD prescription; three-, six-, and 12-month follow-up visits were determined based on subsequent clinical visits and prescription updates, which were documented and compared against previous prescriptions. Prescription changes were used to stratify patients into the second-stage adaptive groups, determined by initiation or termination of bDMARDs at six months. The main outcome was six- and 12-month clinical Juvenile Arthritis Disease Activity Score (cJADAS); the secondary outcome was 12-month Pediatric Quality of Life Inventory (PedsQL) generic total score.Final analysis included 465 patients: 330 in the conservative treatment group and 135 in the aggressive treatment group. Both groups presented improvements in cJADAS and PedsQL. The early aggressive approach was, compared to the conservative approach, superior in six-month cJADAS reduction (mean, &minus;2.17; 95%&thinsp;confidence interval [CI], &minus;3.77 to &minus;0.56). The addition of bDMARD six months after baseline was not beneficial.&ldquo;Similarly to the cJADAS results, the early aggressive group presented worse quality of life at the baseline, but similar scores at the 6 and 12&thinsp;months of follow-up, with PedsQL scores (mean&plusmn;SD) 61.35&plusmn;19.24 versus 67.58&plusmn;17.53 at baseline, 73.40&plusmn;17.42 versus 74.34&plusmn;19.38 at 6&thinsp;months and 76.32&plusmn;16.47 versus 78.52&plusmn;18.63 at 12&thinsp;months,&rdquo; the authors added.The researchers concluded, &ldquo;All treatment strategies show significant improvement from the baseline. The study results suggest that, compared with csDMARD only, early aggressive use of bDMARD in treating patients with pcJIA soon after diagnosis achieves more than two points of additional reduction in disease activity at 6 months.&rdquo;

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

‘Timing Matters’: Treat Juvenile Idiopathic Arthritis Aggressively and Early with bDMARDs, Researchers Say

Rheumatology

A recent study concluded that “timing matters” and that early, aggressive treatment trumps delayed, conservative treatment in children with newly diagnosed polyarticular ...

‘Timing Matters’: Treat Juvenile Idiopathic Arthritis Aggressively and Early with bDMARDs,

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe